Researchers at The University of Texas MD Anderson Cancer Center have uncovered a concealed mechanism enabling T cells to target acute myeloid leukemia (AML) independently of the conventional MHC recognition system. A comprehensive genome-wide CRISPR analysis identified CD64 as a significant element, and further investigations revealed that T cells still depended on a functional T cell receptor (TCR). This phenomenon was noted across numerous AML cell lines and patient samples, encompassing relapsed cases and high-risk mutations. The team is currently exploring the interaction between CD64 and TCR signaling, assessing the potential of this mechanism to enhance future cancer therapies.
Disclosure: This video contains stock footage and content created or enhanced using Al-assisted tools.
ai-generated
